The hepatitis C cascade of care in HIV/hepatitis C virus coinfected individuals in Europe: regional and intra-regional differences. (1st March 2022)

• Record Type: Journal Article
• Authors: Fursa, Olga; Mocroft, Amanda; Lazarus, Jeffrey V.; Amele, Sarah; Lundgren, Jens; Matulionyte, Raimonda; Rasmussen, Line D.; Rockstroh, Jürgen K.; Parczewski, Milosz; Jilich, David; Moreno, Santiago; Vassilenko, Anna; Lacombe, Karine; Wandeler, Gilles; Borodulina, Elena; Brännström, Johanna; Wiese, Lothar; Orkin, Chloe; Behrens, Georg M.N.; Mansinho, Kamal; Portu, Jose Joaquin; Peters, Lars
• Other Names: collaborator.
• Is Part Of: AIDS. Volume 36:Number 3(2022)
• Page Start: 423
• Page End: 435
• Publication Date: 2022-03-01
• Subjects: cascade of care -- Europe -- hepatitis C -- HIV/hepatitis C virus coinfection -- viral hepatitis elimination; AIDS (Disease) -- Periodicals; Acquired Immunodeficiency Syndrome; AIDS (Disease); Periodicals; Periodicals; 616.9792005
• DOI: 10.1097/QAD.0000000000003112
• Languages: English
• ISSNs: 0269-9370

Abstract

Abstract : Background: Following the introduction of direct-acting antiviral therapy in 2013, WHO launched the first Global Health Sector Strategy on Viral Hepatitis. We describe a hepatitis C virus (HCV) cascade of care in people with HIV (PWH) across Europe in terms of reaching the WHO elimination targets of diagnosing 90% and treating 80% of HCV-infected individuals. Methods: HIV/HCV-coinfected participants in the EuroSIDA cohort under prospective follow-up at October 1, 2019, were described using a nine-stage cascade of care. Care cascades were constructed across Europe, on a regional ( n = 5) and country ( n = 21) level. Results: Of 4773 anti-HCV positive PWH, 4446 [93.1%, 95% confidence interval (CI) 92.4–93.9)] were ever tested for HCV RNA, and 19.0% (95% CI 16.4–21.6) were currently HCV RNA positive, with the highest prevalence in Eastern and Central-Eastern Europe (33.7 and 29.6%, respectively). In Eastern Europe, 78.1% of the estimated number of chronic infections have been diagnosed, whereas this proportion was above 95% in the other four regions. Overall, 3116 persons have ever started treatment (72.5% of the ever chronically infected, 95% CI 70.9–74.0) and 2404 individuals (55.9% of the ever chronically infected, 95% CI 53.9–57.9) were cured. Cure proportion ranged from 11.2% in Belarus to 87.2% in Austria. Conclusion: In all regions except Eastern Europe, more than 90% of the study participants have been tested for HCV-RNA. In Southern and Central-Western regions, more than 80% ever chronically HCV-infected PWH received treatment. The proportion with cured HCV infection did not exceed 80% in any region, with significant heterogeneity between countries. Summary: In a pan-European cohort of PWH, all regions except Eastern Europe achieved the WHO target of diagnosing 90% of chronic HCV infections, while the target of treating 80% of eligible persons was achieved in none of the five regions.